In a phase 2 randomized clinical trial (NCT04425538) assessing the efficacy of a single dose of 5 mg/kg infliximab in 18 hospitalized adult patients with severe or critical COVID-19 (treated previously with remdesivir and dexamethasone), the results revealed an immediate abrogation of inflammatory markers (i.e., significant declines in IFN-γ, TNF-α, IL-6, IL-27, CRP, and ferritin observed explicitly at day three post-treatment), as well as remarkable clinical recovery. Here, CRP is linked to COVID-19.